Not surprisingly GlaxoSmithKline has taken its diabetes drug Rosiglitazone off shelves in India.
http://www.thehindubusinessline.com/2010/10/29/stories/2010102952200100.htm
In other news from India and a sign of things to come perhaps Pfizer has a collaborative deal with India-based Biocon aimed at "gaining an edge on the generics market for diabetes products that will expand after 2014 due to patent expirations".
http://www.thehindubusinessline.com/2010/10/29/stories/2010102952200100.htm
In other news from India and a sign of things to come perhaps Pfizer has a collaborative deal with India-based Biocon aimed at "gaining an edge on the generics market for diabetes products that will expand after 2014 due to patent expirations".
